NASDAQ$COLL
Collegium Pharmaceutical Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Collegium reported strong Q2 2024 financial results, driven by record Belbuca revenue and disciplined expense management.
Collegium Pharmaceutical, Inc. reported a 7% increase in product revenues, net, reaching $145.3 million for Q2 2024. GAAP net income increased by 51% year-over-year to $19.6 million, and adjusted EBITDA rose by 12% to $96.0 million. The company reaffirmed its full-year 2024 guidance and is on track to close the acquisition of Ironshore Therapeutics in Q3 2024.
- Net revenue for Q2 2024 was $145.3 million.
- Belbuca revenue reached a record $52.2 million, up 21% year-over-year.
- GAAP net income for Q2 2024 was $19.6 million, a 51% increase year-over-year.
- Adjusted EBITDA for Q2 2024 was $96.0 million, up 12% year-over-year.
Headline financials
Revenue & EPS history
Collegium · Revenue · Quarterly
$145M
Revenue by segment
Collegium · $133M total across 3 segments · Q3 2023
- Nucynta Franchise$47.5M—35.8%
- Belbuca$45.4M—34.2%
- Xtampza ER$39.8M—30.0%
Forward guidance
Collegium reaffirmed its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA for its current business, not including the impact of the planned acquisition of Ironshore.
Tailwinds
- Product Revenues, Net: $580.0 to $595.0 million
- Adjusted Operating Expenses (Excluding Stock-Based Compensation): $120.0 to $125.0 million
- Adjusted EBITDA (Excluding Stock-Based Compensation): $380.0 to $395.0 million
- Acquisition of Ironshore Therapeutics expected to close in Q3 2024
- Acquisition expected to be immediately accretive to adjusted EBITDA.
Headwinds
- Full-year 2024 guidance does not include the impact of the planned acquisition of Ironshore.
- The company expects to update guidance to include Ironshore after closing of the acquisition.
- Uncertainty regarding successful integration of Ironshore's operations.
- Risks related to future opportunities and plans for products.
- Potential difficulties in managing relationships with licensors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+2.6%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
61%
28 / 46 earnings
Positive
+31.2%
Q3 2019
Best reaction
-17.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | -2.2% | -8.9% | |
| Q4 2025 | -3.5% | -12.6% | -29.1% | |
| Q3 2025 | +4.4% | +16.5% | +17.8% | |
| Q1 2025 | +5.9% | +6.6% | +10.7% | |
| Q4 2024 | +2.2% | +0.2% | +4.5% | |
| Q3 2024 | -6.8% | -9.0% | -13.1% | |
| Q2 2024 | +2.5% | +5.9% | +7.3% | |
| Q1 2024 | -17.2% | -12.5% | -12.8% | |
| Q4 2023 | +14.5% | +15.8% | +25.1% | |
| Q3 2023 | +4.6% | +10.8% | +23.0% | |
| Q2 2023 | +6.8% | +9.5% | +7.9% | |
| Q1 2023 | +3.6% | +6.4% | -2.2% | |
| Q4 2022 | +1.7% | +0.5% | -10.0% | |
| Q3 2022 | +6.9% | +11.9% | +30.6% | |
| Q2 2022 | +11.4% | +7.2% | -1.0% | |
| Q1 2022 | +1.7% | +10.0% | +15.9% | |
| Q4 2021 | -14.0% | -17.7% | -14.1% | |
| Q3 2021 | -5.3% | +1.0% | -12.5% | |
| Q2 2021 | -17.6% | -23.7% | -19.2% | |
| Q1 2021 | +3.6% | -0.3% | -1.8% | |
| Q4 2020 | -9.6% | -14.1% | -8.8% | |
| Q3 2020 | +2.2% | +4.3% | +1.9% | |
| Q2 2020 | +6.6% | +13.4% | +16.4% | |
| Q1 2020 | +9.4% | +16.2% | +0.3% | |
| Q4 2019 | +5.2% | -1.5% | -27.4% | |
| Q3 2019 | +31.2% | +38.5% | +53.5% | |
| Q2 2019 | +4.0% | +9.6% | +0.9% | |
| Q1 2019 | +5.6% | -2.9% | -18.0% | |
| Q4 2018 | +18.5% | +22.4% | +2.0% | |
| Q3 2018 | -0.4% | +10.8% | +23.1% | |
| Q2 2018 | -5.7% | -2.0% | -15.7% | |
| Q1 2018 | +11.6% | +8.6% | +9.7% | |
| Q4 2017 | +17.9% | +6.3% | -11.9% | |
| Q3 2017 | +25.8% | +44.7% | +75.2% | |
| Q2 2017 | -4.2% | -0.1% | -2.4% | |
| Q1 2017 | +12.5% | +11.5% | +28.0% | |
| Q4 2016 | +7.9% | +7.4% | -34.6% | |
| Q3 2016 | +7.9% | +1.8% | -0.1% | |
| Q2 2016 | -13.1% | -9.7% | -23.8% | |
| Q1 2016 | -3.0% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -10.4% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q1 2014 | -0.8% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro